Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Gene Ther ; 10(3): 206-12, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12571627

ABSTRACT

The efficacy of replication-deficient adenoviral vectors in gene therapy is confined to the number of tumor cells the vector infects. To focus and enhance the therapeutic efficacy, we employed a conditionally replication-competent adenoviral vector with a tissue-specific promoter, DF3/MUC1, in a human esophageal adenocarcinoma model. Our results demonstrate that Ad.DF3.E1A.CMV.TNF (Ad.DF3.TNF) specifically replicates in Bic-1 (DF3-producing cells) and mediates an enhanced biologic effect due to increased TNF-alpha in the same DF3-producing cells. We also show that the increased TNF-alpha interacts with ionizing radiation to produce greater tumor regression and a greater delay in tumor regrowth in Bic-1 (DF3-producing cells) compared to Seg-1 (DF3 non-producers). Tumor cell targeting using conditionally replication-competent adenoviral vectors with tumor-specific promoters to drive viral replication and deliver TNF-alpha provides a novel approach to enhancing tumor radiosensitivity.


Subject(s)
Adenocarcinoma/therapy , Esophageal Neoplasms/therapy , Genetic Therapy/methods , Mucin-1/genetics , Peptide Fragments/genetics , Adenocarcinoma/immunology , Adenocarcinoma/radiotherapy , Adenoviridae/genetics , Animals , Combined Modality Therapy , Esophageal Neoplasms/immunology , Esophageal Neoplasms/radiotherapy , Genetic Vectors/administration & dosage , Green Fluorescent Proteins , Humans , Luminescent Proteins/genetics , Mice , Mice, Nude , Models, Animal , Mucin-1/analysis , Peptide Fragments/analysis , Promoter Regions, Genetic , Random Allocation , Transplantation, Heterologous , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/biosynthesis , Virus Replication
2.
Dis Colon Rectum ; 44(2): 284-7, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11227948

ABSTRACT

Strictureplasties have proven useful and safe in Crohn's disease. Concerns have been raised, however, about the potential of carcinoma arising at the strictureplasty site. Here the authors report a case of a small-bowel adenocarcinoma developing at the site of a prior strictureplasty in a middle-aged male patient seven years postoperatively in the absence of any other preneoplastic disease of the small bowel. Presenting symptoms were of progressive obstruction after a long period of quiescent disease. With this report comes stronger evidence that adenocarcinoma does occur at strictureplasty sites, raising questions of its long-term safety.


Subject(s)
Adenocarcinoma/etiology , Crohn Disease/surgery , Intestinal Neoplasms/etiology , Postoperative Complications/epidemiology , Adenocarcinoma/diagnosis , Adenocarcinoma/epidemiology , Humans , Intestinal Neoplasms/diagnosis , Intestinal Neoplasms/epidemiology , Male , Middle Aged , Postoperative Complications/diagnosis , Time Factors
3.
Cancer J ; 6(5): 287-93, 2000.
Article in English | MEDLINE | ID: mdl-11079167

ABSTRACT

PURPOSE: The purpose of this study was to evaluate whether endostatin, an antiangiogenic cleavage fragment of collagen XVIII, enhances the antitumor effects of ionizing radiation (IR). Endostatin was injected to coincide with fractionated radiotherapy. METHODS: Xenografts of radioresistant SQ-20B tumor cells were established in athymic nude mice. Lewis lung carcinoma cells were injected into C57BI/6 mice. Mice bearing SQ-20B xenografts were injected intraperitoneally with 2.5 mg/kg/day of murine recombinant endostatin 5 times per week for 2 weeks 3 hours before IR treatment (50 Gy total dose). Mice bearing Lewis lung carcinoma tumors were injected intraperitoneally with endostatin (2.5 mg/kg/day) four times; the first injection was given 24 hours before the first IR dose (15 Gy) and then 3 hours before IR (15 Gy/day) for 3 consecutive days. Microvascular density was assessed on tumor tissue sections by use of CD31 immunohistochemistry and light microscopy. Endothelial cell survival analyses were employed to evaluate endostatin effects on human aortic endothelial cells and human umbilical vein endothelial cells. Endothelial cell apoptosis was examined by use of FACS analysis and DAPI microscopy. RESULTS: In SQ-20B xenografts, combined treatment with endostatin and IR produced tumor growth inhibition that was most pronounced at the nadir of regression (day 21). By day 35, tumors receiving combined treatment with endostatin and IR were 47% smaller than tumors treated with endostatin alone. Interactive cytotoxic treatment effects between endostatin and IR were also demonstrated in mice bearing Lewis lung carcinoma tumors. Significant tumor growth inhibition was observed in the endostatin/IR group at days 11 and 13 compared with IR alone. Histologic analyses demonstrated a reduction in microvascular density after combined treatment with endostatin and IR compared with endostatin treatment alone. Survival analyses confirmed interactive cytotoxicity between endostatin and IR in both human aortic endothelial cells and human umbilical vein endothelial cells but not in SQ-20B tumor cells. Combined treatment with endostatin and IR produced an increase in cow pulmonary artery endothelial apoptosis compared with either treatment alone. DISCUSSION: The tumor regression observed after combined treatment with endostatin and IR suggests additive antitumor effects in both human and murine tumors. Importantly, the concentrations of endostatin employed produced little tumor regression when endostatin was employed as a single agent. The results from the clonogenic and apoptosis assays support the hypothesis that the endothelial compartment is the target for the endostatin/IR interaction.


Subject(s)
Antineoplastic Agents/therapeutic use , Collagen/therapeutic use , Neoplasms/drug therapy , Neoplasms/radiotherapy , Peptide Fragments/therapeutic use , Radiation, Ionizing , Animals , Apoptosis , Carcinoma, Lewis Lung/drug therapy , Cell Separation , Cells, Cultured , Cloning, Molecular , Collagen Type XVIII , Combined Modality Therapy , Dose-Response Relationship, Drug , Endostatins , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Escherichia coli/metabolism , Female , Flow Cytometry , Humans , Immunohistochemistry , Mice , Mice, Inbred C57BL , Microcirculation/drug effects , Microcirculation/radiation effects , Neoplasm Transplantation , Neoplasms/metabolism , Pichia/metabolism , Platelet Endothelial Cell Adhesion Molecule-1/biosynthesis , Recombinant Proteins/metabolism , Time Factors , Tumor Cells, Cultured , Umbilical Veins/cytology , Umbilical Veins/drug effects
4.
Cancer Res ; 60(24): 6958-63, 2000 Dec 15.
Article in English | MEDLINE | ID: mdl-11156396

ABSTRACT

We examined the effects of a new antiangiogenic isocoumarin, NM-3, as a radiation modifier in vitro and in vivo. The present studies demonstrate that NM-3 is cytotoxic to human umbilical vein endothelial cells (HUVECs) but not to Lewis lung carcinoma (LLC) cells nor Seg-1, esophageal adenocarcinoma cells, in clonogenic survival assays. When HUVEC cultures are treated with NM-3 combined with ionizing radiation (IR), additive cytotoxicity is observed. In addition, the combination of NM-3 and IR inhibits HUVEC migration to a greater extent than either treatment alone. The effects of treatment with NM-3 and IR were also evaluated in tumor model systems. C57BL/6 female mice bearing LLC tumors were given injections for 4 consecutive days with NM-3 (25 mg/kg/day) and treated with IR (20 Gy) for 2 consecutive days. Combined treatment with NM-3 and IR significantly reduced mean tumor volume compared with either treatment alone. An increase in local tumor control was also observed in LLC tumors in mice receiving NM-3/IR therapy. When athymic nude mice bearing Seg-1 tumor xenografts were treated with NM-3 (100 mg/kg/day for 4 days) and 20 Gy (four 5 Gy fractions), significant tumor regression was observed after combined treatment (NM-3 and IR) compared with IR alone. Importantly, no increase in systemic or local tissue toxicity was observed after combined treatment (NM-3 and IR) when compared with IR alone. The bioavailability and nontoxic profile of NM-3 suggests that the efficacy of this agent should be tested in clinical radiotherapy.


Subject(s)
Coumarins/pharmacology , Neoplasms/drug therapy , Neoplasms/radiotherapy , Adenocarcinoma/drug therapy , Animals , Carcinoma, Lewis Lung/drug therapy , Cell Movement/drug effects , Cell Movement/radiation effects , Cells, Cultured , Collagen/metabolism , Coumarins/toxicity , Dose-Response Relationship, Drug , Dose-Response Relationship, Radiation , Drug Combinations , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Endothelium, Vascular/radiation effects , Esophageal Neoplasms/drug therapy , Female , Humans , Isocoumarins , Laminin/metabolism , Mice , Mice, Inbred C57BL , Mice, Nude , Neoplasm Transplantation , Proteoglycans/metabolism , Radiation, Ionizing , Time Factors , Tumor Cells, Cultured , Umbilical Veins/cytology , Umbilical Veins/drug effects , Umbilical Veins/radiation effects
5.
Cancer Res ; 59(14): 3374-8, 1999 Jul 15.
Article in English | MEDLINE | ID: mdl-10416597

ABSTRACT

The family of vascular endothelial growth factor (VEGF) proteins include potent and specific mitogens for vascular endothelial cells that function in the lation of angiogenesis Inhibition of VEGF-induced angiogenesis either by neutralizing antibodies or dominant-negative soluble receptor, blocks the growth of primary and metastatic experimental tumors Here we report that VEGF expression is induced in Lewis lung carcinomas (LLCs) both in vitro and vivo after exposure to ionizing radiation (IR) and in human tumor cell lines (Seg-1 esophageal adenocarcinoma, SQ20B squamous cell carcinoma, T98 and U87 glioblastomas, and U1 melanoma) in vitro. The biological significance of IR-induced VEGF production is supported by our finding that treatment of tumor-bearing mice (LLC, Seg-1, SQ20B, and U87) with a neutralizing antibody to VEGF-165 before irradiation is associated with a greater than additive antitumor effect. In vitro, the addition of VEGF decreases IR-induced killing of human umbilical vein endothelial cells, and the anti-VEGF treatment potentiates IR-induced lethality of human umbilical vein endothelial cells. Neither recombinant VEGF protein nor neutralizing antibody to VEGF affects the radiosensitivity of tumor cells These findings support a model in which induction of VEGF by IR contributes to the protection of tumor blood vessels from radiation-mediated cytotoxicity and thereby to tumor radioresistance.


Subject(s)
Antibodies, Monoclonal/pharmacology , Endothelial Growth Factors/antagonists & inhibitors , Gene Expression Regulation, Neoplastic/drug effects , Lymphokines/antagonists & inhibitors , Neoplasm Proteins/antagonists & inhibitors , Neoplasms, Experimental/radiotherapy , Neovascularization, Pathologic/physiopathology , Radiation-Sensitizing Agents/pharmacology , Stress, Physiological/physiopathology , Adenocarcinoma/genetics , Adenocarcinoma/pathology , Adenocarcinoma/radiotherapy , Animals , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/radiotherapy , Cells, Cultured , Culture Media, Conditioned , Endothelial Growth Factors/immunology , Endothelial Growth Factors/physiology , Endothelium, Vascular/cytology , Esophageal Neoplasms/genetics , Esophageal Neoplasms/pathology , Esophageal Neoplasms/radiotherapy , Female , Glioblastoma/genetics , Glioblastoma/pathology , Glioblastoma/radiotherapy , Humans , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Lymphokines/immunology , Lymphokines/physiology , Melanoma/genetics , Melanoma/pathology , Melanoma/radiotherapy , Mice , Mice, Inbred C57BL , Mice, Nude , Neoplasm Proteins/immunology , Neoplasm Proteins/physiology , Neoplasm Transplantation , Neoplasms, Experimental/blood supply , Neoplasms, Experimental/complications , Neoplasms, Experimental/physiopathology , RNA, Messenger/biosynthesis , RNA, Neoplasm/biosynthesis , Radiation Tolerance/drug effects , Stress, Physiological/genetics , Tumor Cells, Cultured/metabolism , Tumor Cells, Cultured/radiation effects , Tumor Stem Cell Assay , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
6.
J Exp Med ; 185(1): 171-5, 1997 Jan 06.
Article in English | MEDLINE | ID: mdl-8996253

ABSTRACT

Several inflammatory cytokines, most notably tumor necrosis factor (TNF) and IL-1, induce anorexia and loss of lean body mass, common manifestations of acute and chronic inflammatory conditions. In C57BL/6 female mice, the administration of TNF, IL-1, and, to a lesser extent, leukemia inhibitory factor (LIF), produced a prompt and dose-dependent increase in serum leptin levels and leptin mRNA expression in fat. IL-10, IL-4, ciliary neurotrophic factor, and IL-2, cytokines not known to induce anorexia or decrease food intake, had no effect on leptin gene expression or serum leptin levels. After administration of Escherichia coli lipopolysaccharide (LPS), leptin gene expression and leptin levels were increased. These findings suggest that leptin levels may be one mechanism by which anorexia is induced during acute inflammatory conditions.


Subject(s)
Adipose Tissue/metabolism , Anorexia , Cytokines/pharmacology , Inflammation , Interleukin-6 , Protein Biosynthesis , Transcription, Genetic/drug effects , Adipose Tissue/drug effects , Adipose Tissue/immunology , Animals , Ciliary Neurotrophic Factor , Escherichia coli , Female , Growth Inhibitors/pharmacology , Humans , Interleukin-10/pharmacology , Interleukin-2/pharmacology , Interleukin-4/pharmacology , Interleukins/pharmacology , Kinetics , Leptin , Leukemia Inhibitory Factor , Lipopolysaccharides/pharmacology , Lymphokines/pharmacology , Mice , Mice, Inbred C57BL , Nerve Tissue Proteins/pharmacology , Proteins/analysis , RNA, Messenger/biosynthesis , Recombinant Proteins/pharmacology , Tumor Necrosis Factor-alpha/pharmacology
7.
Surgery ; 122(6): 1183-7; discussion 1187-8, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9426436

ABSTRACT

BACKGROUND: The role of "blind" thyroid lobectomy in the surgical management of patients with persistent or recurrent primary hyperparathyroidism is not known. We reviewed our experience with reoperation for hyperparathyroidism to determine the utility of blind thyroid resection in this setting. METHODS: From 1982 to 1995, 269 patients underwent reoperation for hyperparathyroidism at our institution. All patients had biochemical confirmation of hyperparathyroidism and underwent noninvasive and if necessary invasive localization studies. Patients who underwent thyroid lobectomy in an attempt to extirpate the hyperfunctioning parathyroid gland form the basis of this report. RESULTS: Thirty-two of 269 patients (12%) underwent thyroid lobectomy to remove a parathyroid gland. Intrathyroidal parathyroids were confirmed in 19 of 32 patients (59%). In 18 of 19 patients (94%), preoperative or intraoperative ultrasonography correctly identified an intrathyroidal lesion suspicious or a parathyroid. Only 1 of 6 patients (17%) undergoing a blind thyroidectomy had an intrathyroidal gland identified. Ultrasonography had a sensitivity of 95% and a negative predictive value of 99.5% in detecting an intrathyroidal parathyroid gland. CONCLUSIONS: The prevalence of an intrathyroidal parathyroid gland in our series is low (19 of 269, 7%). Ultrasonography can be used reliably to select patients for thyroid resection, reducing the need to perform a blind thyroid lobectomy and avoiding the potential morbidity of thyroid resection in this clinical setting.


Subject(s)
Hyperparathyroidism/surgery , Thyroidectomy , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Recurrence , Reoperation
8.
Surgery ; 120(6): 1055-62; discussion 1062-3, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8957495

ABSTRACT

BACKGROUND: Surgical excision of gastrinomas in patients with Zollinger-Ellison syndrome (ZES) decreases the incidence of hepatic metastases, but long-term biochemical cures are achieved in fewer than 30% of cases. A growing number of patients have persistent or recurrent disease after initial operation. The effect of reoperation in these patients has not been previously reported. METHODS: From December 1982 to August 1995, 120 patients with ZES underwent operation for gastrinoma resection. Seventy-eight patients had recurrent or persistent ZES after operation; 17 patients underwent 18 reoperations. After initial operation all patients underwent yearly functional and imaging studies. If a tumor was unequivocally imaged, reexploration was done. RESULTS: Five patients, all with sporadic disease, were disease free after operation, with a median follow-up of 28 months. Tumor was found in all 18 reoperations and resected in 17. In patients with continuing disease-free intervals, locations of gastrinomas included pancreatic head lymph nodes (three), liver metastasis (one), and pancreatic tail lymph node (one). There were no deaths in the cured group; two patients in the group with persistent disease have died (median follow-up, 34 months). CONCLUSIONS: Reoperation for gastrinoma excision resulted in elimination of disease in 30% of patients and should be considered for patients with imageable disease.


Subject(s)
Gastrinoma/surgery , Pancreatic Neoplasms/surgery , Zollinger-Ellison Syndrome/surgery , Adult , Aged , Female , Humans , Male , Middle Aged , Neoplasm Recurrence, Local , Postoperative Complications , Reoperation
9.
Anal Biochem ; 191(1): 156-9, 1990 Nov 15.
Article in English | MEDLINE | ID: mdl-2077937

ABSTRACT

Plasma disaturated phosphatidylcholine (DSPC) concentration has been implicated as a risk factor for atherosclerosis. However, suitable methods for the estimation of these compounds in plasma are not available. In this paper, a method for the estimation of DSPC using argentation thin-layer chromatography and high-performance liquid chromatography is described. It is quantitative for the measurement of individual and total DSPC species and is not dependent on fatty acid chain length. The method employs hydrolysis of total plasma phosphatidyl choline by phospholipase C, followed by benzoylation of the diacylglycerols. The benzoates are then fractionated on silver nitrate-impregnated silica gel thin-layer chromatography plates, and the disaturated species separated and quantitated by high-performance liquid chromatography. The method is sensitive and reproducible and allows many samples to be done at once. With this method, the amounts of DSPC were found to be significantly higher in a group of normolipidemic diabetic subjects, compared to age-matched controls.


Subject(s)
Chromatography, High Pressure Liquid/methods , Phosphatidylcholines/blood , Chromatography, Thin Layer , Diabetes Mellitus/blood , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...